Immuneering Announces Participation in Upcoming Investor Conferences
January 24 2022 - 6:50AM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
advancing a robust pipeline of oncology and neuroscience product
candidates that are designed to uniquely disrupt cellular signaling
dynamics, today announced that Ben Zeskind, Ph.D., Co-Founder,
President and Chief Executive Officer of Immuneering, Biren Amin,
MBA, Chief Financial Officer and Brett Hall, Ph.D., Chief
Scientific Officer, will participate in upcoming investor
conferences to share commentary with investors around the Company’s
pipeline, platform and business strategy.
Immuneering will present virtually at the following
conferences:
B. Riley Securities Virtual
Oncology Investor Conference
- Format: Company Presentation and 1x1 Meetings
- Presentation Date and Time: January 28, 2022 at 12:00 pm
ET
- Webcast and Replay:
https://www.webcaster4.com/Webcast/Page/2828/44143
Guggenheim Virtual Oncology Conference
- Format: Fireside Chat and 1x1 Investor
Meetings
- Presentation Date and Time: February
9, 2022 at 10:00 am ET
- Webcast and Replay:
https://kvgo.com/2022-oncology-conference/immuneering-corp-feb
The presentations will be webcast live and archived in the
Investor Relations section of Immuneering’s website at Events &
Presentations | Immuneering Corporation for 30 days.
About Immuneering CorporationImmuneering aims
to improve patient outcomes by advancing a unique pipeline of
oncology and neuroscience product candidates developed using its
translational bioinformatics platform. Immuneering has more than a
decade of experience applying translational bioinformatics to
generate insights into drug mechanism of action and patient
treatment response. Building on this experience, Immuneering’s
disease-agnostic discovery platform enables the company to create
product candidates based on 1) biological insights that are both
counterintuitive and deeply rooted in data, and 2) novel chemistry.
Immuneering’s lead product candidate IMM-1-104 is designed to be a
highly selective dual-MEK inhibitor that further disrupts KSR to
modulate the signaling dynamics of the MAPK pathway. Specifically,
it is designed to use deep cyclic inhibition to deprive tumor cells
of the sustained proliferative signaling required for rapid growth,
while providing a cadenced, moderate level of signaling sufficient
to spare healthy cells. IMM-1-104 is being developed to treat
advanced solid tumors in patients harboring RAS mutant tumors,
guided by Immuneering’s proprietary, human-aligned 3D tumor
modeling platform combined with translational bioinformatics and
expertise in translational planning. In addition to IMM-1-104,
Immuneering has six other oncology programs in the discovery stage
that are designed to target either the MAPK or mTOR pathway, and
two neuroscience programs in the discovery stage.
Forward-Looking Statements
This press release includes certain disclosures that contain
"forward-looking statements." Forward-looking statements are based
on Immuneering’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, the risks inherent in oncology and neuroscience
drug development, including target discovery, target validation,
lead compound identification, lead compound optimization,
preclinical studies and clinical trials. These and other risks and
uncertainties are described more fully in the section titled "Risk
Factors" in the final prospectus related to the offering filed with
the U.S. Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date,
and Immuneering undertakes no duty to update such information
except as required under applicable law.
Corporate
Contact:Rebecca Kusko, Ph.D.Immuneering
Corporation617-500-8080rkusko@immuneering.com
Investor
Contact:Susan A. NoonanS.A. Noonan
Communicationssusan@sanoonan.com917-513-5303
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024